focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) Pfizer Inc

27 May 2014 11:53

RNS Number : 1179I
Morgan Stanley Capital Services LLC
27 May 2014
 



 

 FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Morgan Stanley Capital Services LLC

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

PFIZER INC

(c) Name of the party to the offer with which exempt principal trader is connected:

 

ASTRAZENECA PLC

(d) Date dealing undertaken:

23 MAY 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

 Class of relevant security

 Purchases/sales

 Total number of securities

 Highest price per unit paid/received

 Lowest price per unit paid/received

 COMMON STOCK

 PURCHASES

 156,256

 29.6200 USD

 29.4300 USD

 COMMON STOCK

 SALES

 78,696

 29.6300 USD

 29.4400 USD

 

 

(b) Derivatives transactions (other than options)

 

 Class of relevant security

 Product description

e.g. CFD

 Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

 Number of reference securities

 Price per unit

 COMMON STOCK

 CFD

 LONG

 1,500

 29.4826 USD

 COMMON STOCK

 CFD

 LONG

 100

 29.4850 USD

 COMMON STOCK

 CFD

 LONG

 1,000

 29.4862 USD

 COMMON STOCK

 CFD

 LONG

 1,954

 29.4926 USD

 COMMON STOCK

 CFD

 LONG

 287

 29.4926 USD

 COMMON STOCK

 CFD

 LONG

 200

 29.5000 USD

 COMMON STOCK

 CFD

 LONG

 16,100

 29.5161 USD

 COMMON STOCK

 CFD

 LONG

 300

 29.5666 USD

 COMMON STOCK

 CFD

 LONG

 674

 29.5904 USD

 COMMON STOCK

 CFD

 LONG

 7,411

 29.5904 USD

 COMMON STOCK

 CFD

 LONG

 48,870

 29.5960 USD

 COMMON STOCK

 CFD

 LONG

 300

 29.6233 USD

 COMMON STOCK

 CFD

 SHORT

 112

 29.4560 USD

 COMMON STOCK

 CFD

 SHORT

 23

 29.4560 USD

 COMMON STOCK

 CFD

 SHORT

 101

 29.4566 USD

 COMMON STOCK

 CFD

 SHORT

 24

 29.4566 USD

 COMMON STOCK

 CFD

 SHORT

 100

 29.4569 USD

 COMMON STOCK

 CFD

 SHORT

 24

 29.4569 USD

 COMMON STOCK

 CFD

 SHORT

 13

 29.4590 USD

 COMMON STOCK

 CFD

 SHORT

 7

 29.4590 USD

 COMMON STOCK

 CFD

 SHORT

 3,300

 29.4728 USD

 COMMON STOCK

 CFD

 SHORT

 1,409

 29.4791 USD

 COMMON STOCK

 CFD

 SHORT

 540

 29.4791 USD

 COMMON STOCK

 CFD

 SHORT

 3,666

 29.4791 USD

 COMMON STOCK

 CFD

 SHORT

 9,561

 29.4791 USD

 COMMON STOCK

 CFD

 SHORT

 3,800

 29.4881 USD

 COMMON STOCK

 CFD

 SHORT

 1

 29.4900 USD

 COMMON STOCK

 CFD

 SHORT

 6

 29.4900 USD

 COMMON STOCK

 CFD

 SHORT

 45,000

 29.4900 USD

 COMMON STOCK

 CFD

 SHORT

 3,200

 29.4900 USD

 COMMON STOCK

 CFD

 SHORT

 2,427

 29.5000 USD

 COMMON STOCK

 CFD

 SHORT

 373

 29.5000 USD

 COMMON STOCK

 CFD

 SHORT

 58

 29.5000 USD

 COMMON STOCK

 CFD

 SHORT

 76

 29.5000 USD

 COMMON STOCK

 CFD

 SHORT

 7,100

 29.5077 USD

 COMMON STOCK

 CFD

 SHORT

 11,421

 29.5233 USD

 COMMON STOCK

 CFD

 SHORT

 22,500

 29.5322 USD

 COMMON STOCK

 CFD

 SHORT

 4,400

 29.5370 USD

 COMMON STOCK

 CFD

 SHORT

 100

 29.5600 USD

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

 Class of relevant security

 Product description e.g. call option

 Writing, purchasing, selling, varying etc.

 Number of securities to which option relates

 Exercise price per unit

 Type e.g. American, European etc.

 Expiry date

 Option money paid/ received per unit

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 

(ii) Exercising

 

 Class of relevant security

 Product description e.g. call option

 Number of securities

 Exercise price per unit

 N/A

 N/A

 N/A

 N/A

 

(d) Other dealings (including subscribing for new securities)

 

 Class of relevant security

 Nature of dealing e.g. subscription, conversion

 Details

 Price per unit (if applicable)

 N/A

 N/A

 N/A

 N/A

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

Date of disclosure:

27 MAY 2014

Contact name:

Darren Wickert

Telephone number:

+44 (0)20 7425 6578

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERBGGDUDUDBGSR
Date   Source Headline
16th Sep 20227:10 amRNSDanicopan Phase III trial met primary endpoint
16th Sep 20227:05 amRNSEvusheld positive CHMP opinion in EU
16th Sep 20227:00 amRNSNirsevimab recommended for approval in EU by CHMP
5th Sep 20227:05 amRNSForxiga approved in China for CKD
5th Sep 20227:00 amRNSImfinzi approved in US for biliary tract cancer
1st Sep 20223:00 pmRNSTotal Voting Rights
30th Aug 20221:00 pmRNSEvusheld approved for COVID-19 in Japan
30th Aug 20227:01 amRNSFarxiga shows CV mortality benefit across EF range
30th Aug 20227:00 amRNSFarxiga reduced risk of CV death or worsening HF
25th Aug 20227:10 amRNSUltomiris approved in Japan for gMG
25th Aug 20227:05 amRNSTagrisso approved in Japan for early lung cancer
25th Aug 20227:00 amRNSLynparza approved in Japan for early breast cancer
16th Aug 20227:00 amRNSLynparza granted FDA priority review for PROpel
15th Aug 20227:00 amRNSEnhertu improved PFS in mBC in DESTINY-Breast02
12th Aug 20227:00 amRNSEnhertu approved in US for HER2-mutant NSCLC
11th Aug 20227:00 amRNSAcquisition of TeneoTwo completed
8th Aug 20227:10 amRNSEnhertu approved in the US for HER2-low mBC
4th Aug 20227:00 amRNSLynparza approved in EU for early breast cancer
1st Aug 20225:00 pmRNSDirector/PDMR Shareholding
1st Aug 20223:05 pmRNSDirector/PDMR Shareholding
1st Aug 20223:00 pmRNSTotal Voting Rights
29th Jul 20227:01 amRNSChair succession
29th Jul 20227:00 amRNSHalf-year Report
25th Jul 20227:10 amRNSTezspire recommended for EU approval in asthma
25th Jul 20227:05 amRNSUltomiris recommended for EU approval for gMG
25th Jul 20227:00 amRNSEnhertu granted Priority Review for HER2-low mBC
19th Jul 20227:00 amRNSEnhertu approved in EU for HER2-positive mBC
5th Jul 20227:00 amRNSAstraZeneca to acquire TeneoTwo and T cell engager
1st Jul 20223:00 pmRNSTotal Voting Rights
30th Jun 20227:00 amRNSImfinzi improved pCR in resectable lung cancer
27th Jun 20227:05 amRNSEnhertu recommended for breast cancer EU approval
27th Jun 20227:00 amRNSLynparza recommended in EU for early breast cancer
21st Jun 20227:00 amRNSEplontersen Ph III trial met co-primary endpoints
6th Jun 20227:00 amRNSEnhertu efficacy results in HER2-low breast cancer
1st Jun 20223:00 pmRNSBlock listing Interim Review
1st Jun 20223:00 pmRNSTotal Voting Rights
20th May 20224:00 pmRNSDirector/PDMR Shareholding
9th May 20221:00 pmRNSAppointment of joint corporate brokers
6th May 20224:00 pmRNSDirector/PDMR Shareholding
5th May 20227:10 amRNSEnhertu approved in US for 2L HER2+ breast cancer
5th May 20227:05 amRNSFarxiga HFpEF Phase III trial met primary endpoint
5th May 20227:00 amRNSUltomiris NMOSD Ph. III trial met primary endpoint
4th May 20227:00 amRNSImfinzi combo granted Priority Review for BTC
3rd May 20223:00 pmRNSTotal Voting Rights
29th Apr 20225:30 pmRNSResult of AGM
29th Apr 20227:05 amRNSAstraZeneca plans new R&D centre in Massachusetts
29th Apr 20227:00 amRNSFirst quarter 2022 results
28th Apr 20227:00 amRNSUltomiris approved in the US for adults with gMG
27th Apr 20227:00 amRNSEnhertu granted BTD for HER2-low breast cancer
25th Apr 20227:00 amRNSTremelimumab US Priority Review for Imfinzi combo

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.